Mobile drug-resistance genes with identical nucleic acid sequences carried by multidrug-resistant Escherichia coli strains that cause community-acquired infections are becomingly increasingly dispersed worldwide. Over a 2-year period, we analysed Gram-negative bacterial (GNB) pathogens from the blood of inpatients at an urban public hospital to determine what proportion of these isolates carried such globally dispersed drug-resistance genes. Of 376 GNB isolates, 167 (44 %) were Escherichia coli, 50 (13 %) were Klebsiella pneumoniae, 25 (7 %) were Pseudomonas aeruginosa, 25 (7 %) were Proteus mirabilis and 20 (5 %) were Enterobacter cloacae; the remainder (24 %) comprised 26 different GNB species. Among E. coli isolates, class 1 integrons were detected in 64 (38 %). The most common integron gene cassette configuration was dfrA17-aadA5, found in 30 (25 %) of 119 drug-resistant E. coli isolates and in one isolate of Moraxella morganii. Extended-spectrum b-lactamase (ESBL) genes were found in 16 E. coli isolates (10 %). These genes with identical sequences were found in nearly 40 % of bloodstream E. coli isolates in the study hospital, as well as in a variety of bacterial species from clinical and non-clinical sources worldwide. Thus, a substantial proportion of bloodstream infections among hospitalized patients were caused by E. coli strains carrying drug-resistance genes that are dispersed globally in a wide variety of bacterial species.
INTRODUCTION
Multidrug-resistant Gram-negative bacteria (GNB) that cause community-onset infections are increasingly being reported from many regions of the world (Ajiboye et al., 2009; Coque et al., 2008; Johnson et al., 2008 Johnson et al., , 2010 Kumarasamy et al., 2010; Peirano & Pitout, 2010; Pitout et al., 2005; Suzuki et al., 2009; Woerther et al., 2010) . The sources of these drug-resistant GNB causing extra-intestinal infections, such as urinary tract infection (UTI), are not obvious. There is increasing evidence that drugresistant extra-intestinal Escherichia coli infections can cause outbreaks in community settings (Enne et al., 2001; Manges et al., 2001 Manges et al., , 2006 Olesen et al., 1994; Smith et al., 2008) . These organisms carry mobile drug-resistance genes that are also recognized globally. Such global spread may be facilitated by widely distributed food products contaminated with drug-resistant GNB that originate in food animal reservoirs, or by person-to-person transmission following foreign travel, including 'medical tourism' (Ajiboye et al., 2009; Johnson et al., 2009; Kumarasamy et al., 2010; Peirano & Pitout, 2010; Vincent et al., 2010) .
Hospitals and outpatient clinical settings are important reservoirs and sources of drug-resistant GNB pathogens and drug-resistance genes. In hospitals, antimicrobial drugs can select for drug-resistant GNB strains that acquire resistance by gene mutation. Antimicrobial agents used in these clinical settings may also facilitate mobile drugresistance genes to transfer across different lineages of the same bacterial species or across different bacterial species by horizontal gene transfer. The prevalence of drugresistant GNB infections among inpatients in hospitals is thus affected by antimicrobial drug-use practices.
It is also recognized that drug-resistant GNBs and their drug-resistance genes circulating in the community can be introduced into hospitals. However, in most hospitals, the relative proportion of infections caused by GNB strains whose resistance is selected in the hospital versus those caused by strains newly introduced into the hospital is not known. This is an important piece of information for infection control in hospitals. In the former, antimicrobial drug-use stewardship may help control such infections. However, if a substantial proportion of GNB infections in a hospital are caused by resistant GNB pathogens newly introduced into the hospital, such an infection-control practice may have a limited effect. Here, we sought to address this question in a large urban hospital, where antimicrobial selective pressures are high. We prospectively examined GNB isolates from patients diagnosed with bloodstream infections (BSIs) and specifically compared the nucleic acid sequences of mobile drug-resistance genes with those genes already recognized to be circulating globally.
METHODS
Strain collection. The clinical microbiology laboratory of San Francisco General Hospital (SFGH) is one of the largest in the Bay Area, and the cultures originated from all hospital wards, as well as from jail clinics and San Francisco's city outpatient clinics. All GNB isolates from BSIs at the clinical microbiology laboratory of SFGH are stored on agar slants for up to 3 months. Every 3 months, these isolates were provided to us for analysis. We examined all consecutively collected GNB BSI isolates from patients admitted as an inpatient to SFGH between July 2007 and September 2009. This study was approved by the University of California, San Francisco Committee on Human Research.
Information on the dates of admission and first blood culture that yielded the GNB pathogen was available for most of the isolates. In this study, we considered BSI to be a community-onset infection if the time period between the date of admission and the first blood culture that grew a GNB pathogen was ¡48 h (Friedman et al., 2002) .
Strain characterization and susceptibility testing. At SFGH, the BSI isolates were speciated biochemically using API 20E (bioMérieux) for fermenters or API 20NE (bioMérieux) for non-enteric bacteria. Antimicrobial susceptibility tests were performed using a Microscan WalkAway Gram-Negative panel (Dade Behring/Siemens). For E. coli organisms, multiple drug resistance was defined as resistance to one or more agents in three or more classes of tested drugs (Johnson et al., 2010; Márquez et al., 2008) . Intermediate susceptibility was classified as resistant. Extended-spectrum b-lactamase (ESBL) production was confirmed by a double-disc diffusion assay according to Clinical and Laboratory Standards Institute (CLSI, 2011) guidelines with cefotaxime and ceftazidime on Luria-Bertani (LB) agar plates with and without clavulanic acid.
DNA extraction and PCR amplification for integron gene cassettes and ESBL gene detection. PCR analysis to detect class 1 integrons was conducted on all isolates. Gene cassette PCR was conducted on all class 1 integrase-positive isolates. PCR analysis to detect b-lactamase genes was conducted on isolates suspected to be ESBL producers by double-disc diffusion assay results. The bacterial DNA was extracted from a single colony on either an LB agar plate or a tryptic soy agar plate using a freeze-thaw method. The colony was suspended in 500 ml water, boiled for 15 min, frozen overnight at 280 uC, reboiled for 15 min and centrifuged for 30 s at 2000 r.p.m. in a bench microfuge. Two microlitres of the supernatant was used as template DNA in a 25 ml reaction buffer containing 1.5 mM MgCl 2 , 0.4 mM dNTPs, 1 U Taq polymerase (Invitrogen), 16 PCR buffer (Invitrogen) and 2 mM each primer. AmpliTaq Gold (Applied Biosystems) was used for gene cassette PCR. PCR products were visualized on a 1 % agarose gel stained with ethidium bromide.
Primer sequences. The primer sequences used have been published previously (Table 1 ). To detect empty integrons, we used the 39-CS primer in conjunction with Int 2 F. We used primers described by others to detect b-lactamase genes (Dallenne et al., 2010; Shibata et al., 2006) . As a positive PCR control for the class 1 integrase PCR, we amplified 16S rRNA gene sequences. For a positive control for the gene cassette and b-lactamase gene PCRs, we used strains confirmed previously by sequencing to contain cassette and b-lactamase genes.
Sequencing amplified gene cassette products. For each PCR product that appeared as a unique band when visualized by gel electrophoresis, 2 ml PCR product was cleaned with 2 ml of a 1 : 10 dilution of ExoSAP-IT (Affymetrix), which was then diluted 100-fold and submitted for direct sequencing. Sequencing was carried out at the University of California Berkeley DNA sequencing facility. The DNA sequences were inspected visually, edited and assembled using BioEdit version 7.0.1. CLUSTAL W was used to perform multiple alignment analyses of the sequences. Sequences were compared for single-nucleotide polymorphisms (SNPs) with gene sequences deposited in the National Center for Biotechnology Information (NCBI) database using an updated version of the BLAST program.
Statistics. Categorical variables were compared by x 2 (with Yates' correction) or Fisher's two-tailed exact tests.
RESULTS
Of 376 BSI isolates collected between July 2007 and September 2009, 167 (44 %) were E. coli, 50 were Klebsiella pneumoniae (13 %), 25 were Pseudomonas aeruginosa (7 %), 25 were Proteus mirabilis (7 %) and 20 were Enterobacter cloacae (5 %). Together, these accounted for 76 % of all isolates. In total, 31 distinct GNB species were identified (Table 2) .
Of 359 isolates with susceptibility data, 279 (78 %) were resistant to at least one antimicrobial class. Of 165 E. coli isolates, 86 (52 %) were multidrug-resistant. The ESBL gene bla CTX-M was identified by PCR in 16 E. coli isolates (Table 3) ; three were bla CTX-M-1 , four were bla CTX-M-14 and nine were bla CTX-M-15 . The b-lactamase gene bla TEM-1 was found in seven E. coli, one Citrobacter freundii and one Enterobacter aerogenes. bla SHV was not detected in any of the isolates. For those isolates showing phenotypic resistance to broad-spectrum antimicrobial agents but lacking the above b-lactamase genes, we performed PCR analysis for plasmidborne ampC-type genes. CIT group and DHA group genes were detected in six such isolates (Table 3) . Additionally, two E. coli isolates with bla CTX-M and one C. freundii isolate with bla TEM also harboured plasmid-borne ampC-type genes.
By PCR analysis, we identified class 1 integrons in 90 isolates (24 %). The five most frequently isolated species accounted for 85 (94 %) of the class 1 integron-containing isolates (Table 3) . Class 1 integrons were found in 64 (38 %) of 167 E. coli isolates and in only two (8 %) of 25 Pseudomonas aeruginosa isolates. Of 117 drug-resistant E. coli isolates, 62 (53 %) harboured class 1 integrons. Among 48 E. coli isolates that were susceptible to all drugs tested, only one (2 %) contained a class 1 integron bearing no detectable gene cassette. Using primers to amplify the integron variable region, we detected gene cassettes in 69 (77 %) of the integron-harbouring isolates. E. coli comprised 48 (70 %) of these. Twenty-one (23 %) of the integrons were 'empty', harbouring no detectable gene cassettes. Four gene cassettes contained partial or non-resistance genes. We were unable to identify conclusively the gene in five of the cassettes.
The most frequent integron cassette genes identified were dihydrofolate reductase A (dfrA) genes dfrA12, dfrA15, dfrA16 and dfrA17, which confer resistance to trimethoprim-sulfamethoxazole (TMP), and aminoglycoside adenyltransferase (aad) genes aadA1, aadA2, aadA5 and aadB, which confer resistance to aminoglycosides (Table  3) . aadA2 was found in combination with dfrA12 in three isolates and alone in three others. There were seven alleles of aadA1, and they were detected in 17 (25 %) of the 69 gene cassettes. One aadA1 allele was found among seven E. coli strains. Another aadA1 allele occurred in one E. coli and one K. pneumoniae strain. The other alleles were mostly unique, distributed among two different GNB species, whilst the other aad genes were found in only one GNB species each. aad cassettes were detected in 23 (58 %) of 40 aminoglycoside-resistant GNB isolates and in 19 (66 %) of 29 aminoglycoside-resistant E. coli isolates, indicating that all strains carrying aad were resistant to an aminoglycoside.
Of 120 BSI isolates that were resistant to TMP, 39 (33 %) were confirmed by PCR to harbour dfr cassette configurations; all The most frequent gene cassette configuration was dfrA17-aadA5, a 1.8 kb sequence. Thirty (48 %) of 62 drugresistant E. coli strains carrying an integron harboured this cassette configuration. An identical sequence was also found in one strain of Morganella morganii (Table 3) .
SNPs of fimH, a gene that encodes the adhesin subunit of E. coli type I pilus, were used to screen E. coli genotypes (Dias et al., 2009; Tartof et al., 2007) . Of 17 distinct fimH SNP types comprising 82 of 87 multidrug-resistant E. coli isolates (five could not be typed), strains belonging to five distinct SNP types carried identical dfrA17-aadA5 sequence.
Of 353 patients with admission date information, 243 (69 %) had a GNB cultured from blood obtained ¡48 h Enterobacter aerogenes
Serratia liquefaciens 3 (0.8) 0 (0) NI NI NI 1 (33) 1 (33) 0 (0) 1 (33) 0 (0) Salmonella species 3 (0.8) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Aeromonas species 2 (0.5) 0 (0) NI NI NI 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Providencia rettgeri 2 (0.5) 0 (0) 1 (50) 2 (100) 1 (50) 1 (50) 1 (50) 1 (50) 0 (0) 0 (0) Proteus vulgaris 2 (0.5) 0 (0) 2 (100) 2 (100) 2 (100) 1 (50) 0 (0) 0 (0) 1 (50) 0 (0) Alcaligenes species 1 (0. Burkholderia cepacia 1 (0.3) 0 (0) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Brevundimonas species 1 (0.3) 0 (0) 0 (0) 1 (100) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Citrobacter koseri 1 (0.3) 0 (0) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Flavimonas oryzihabitans
Leclercia adecarboxylata after admission (Table 4) ; seven (29 %) of the Pseudomonas aeruginosa cases and 236 (72 %) of all other GNB BSI cases had the first positive blood culture obtained ¡48 h after admission (P,0.05) (Table 4 ). Among 30 patients infected with E. coli harbouring the most common drug-resistant cassette configuration (dfrA17-aadA5), 68 % had the first positive blood culture obtained ¡48 h after admission; 53 % were cultured ,24 h after admission. The blood culture from one patient that grew M. morganii harbouring dfrA17-aadA5 was obtained 21 h after admission.
DISCUSSION
Among 167 E. coli BSIs identified between July 2007 and September 2009, 63 (38 %) were caused by strains that harboured three integron cassette genes (aadA1, aadA2 and dfrA17-aadA5) and ESBL genes (bla CTX-M ). These genes were 100 % identical in sequence to those already dispersed globally in a variety of bacterial strains and species isolated from non-hospital sources, including food, water, animals and healthy humans, deposited in the NCBI database. By the definition we used, 78 % of the E. coli BSIs identified at SFGH were community-onset infections (Table 4 ). Among those patients infected with an E. coli strain carrying the most common cassette configuration (dfrA17-aadA5), 68 % were already infected at the time of admission to the study hospital. This large cassette sequence (1.8 kb) was 100 % identical in all of the strains. As this cassette was found in a wide variety of fimH SNP types, it was not likely to have been spread by some biologically 'fit' or epidemic strain in the hospital. In contrast, 32 % of the E. coli strains carrying dfrA17-aadA5 were detected in E. coli cultured from blood after .48 h of hospitalization. It is possible that these strains acquired the cassette by horizontal gene transfer after hospitalization. However, even this observation suggests that this particular cassette configuration was introduced into the hospital sometime earlier and spread subsequently. Interestingly, most (71 %) of the Pseudomonas aeruginosa BSIs appeared to have been hospital acquired; none had the dfrA17-aadA5 configuration.
In fact, dfrA17-aadA5 was the most frequently observed integron cassette configuration found in this study. In the NCBI database, there are 13 different dfrA17 alleles; nine of these differ by 1 nt and four differ by 2-5 nt. There are 16 different aadA5 alleles in the NCBI database, which differ by a 1 nt substitution in most. Therefore, if the mutation frequency of this cassette configuration was identical, over 200 alleles of the dfrA17-aadA5 configuration should be represented in the database. The observation that only one allele of this configuration was represented among SFGH GNB isolates and among many bacterial species and sources around the world suggests that it has undergone horizontal gene transfer as a single 1.8 kb block across many bacterial species.
A study of UTI E. coli isolates collected from a university health centre in the San Francisco Bay Area between 1999 and 2001 also reported dfrA17-aadA5 as the most frequently detected gene cassette configuration . This configuration was found among food animal E. coli isolates from different regions of the USA (Ajiboye et al., 2009) . The most common subtype of this array (GenBank accession no. FJ381673) found in that study was 100 % identical in sequence to the dfrA17-aadA5 sequence found in this BSI study. A study from Korea found this dfrA17-aadA5 sequence to be the most frequently detected type during the period 1996-2002, replacing dfrA12, which was previously found to be the most commonly detected drug-resistance cassette from 1980 to 1985 in that region (Yu et al., 2004) . dfrA17-aadA5 was the only gene cassette isolated from healthy farm workers in China (Li et al., 2010) . Studies of commensal species isolated from healthy humans in Switzerland and Spain detected this same allele, although they reported the dfrA1-aadA1 arrangement to have a higher frequency (Cocchi et al., 2007; Vinué et al., 2008) .
The second most common drug-resistance gene that we found in this study was the ESBL gene bla CTX-M , which was found in 16 (9.6 %) of the E. coli BSI isolates. Of these, more than half (56 %) belonged to bla CTX-M-15 , which is the most common CTX-M type found in ESBL-producing E. coli strains circulating globally, many of which are associated with community-acquired UTIs (Peirano & Pitout, 2010; Pitout & Laupland, 2008; Pitout et al., 2005) . It appears that patients with BSIs diagnosed at our study hospital have become part of this global pandemic caused by CTX-M-expressing E. coli.
There were several limitations to this study. A large proportion (44 %) of BSIs in this study were caused by E. coli. Thus, our observation that a large proportion of drugresistant BSI cases were community-onset infections is limited to E. coli infections and cannot be generalized to other GNB infections. Another limitation is that we did not have detailed information on the setting of infections of the study subjects. The so-called community-onset cases could have had prior health-care-setting exposures. However, even if many of these patients acquired their E. coli strains harbouring drug-resistance genes at a health-care setting elsewhere prior to being admitted to the study hospital, the fact remains that they were already infected at the time of admission and that for them, the antimicrobial stewardship practised at this hospital would not have prevented these infections.
Thus, it appears that the prevalence of drug-resistant BSIs in a local setting, such as a hospital in San Francisco, can be affected by globally circulating mobile drug-resistance genes, in addition to the antimicrobial drug selective pressure in the hospital. The BSI prevalence we estimated to be due to drug-resistant E. coli strains newly introduced into the hospital may be an underestimate, as we only examined integrons and some of the ESBL genes. We did not examine other mobile genes known to be dispersed globally, such as those encoding metallo-b-lactamases (Kumarasamy et al., 2010; Peleg & Hooper, 2010; Pitout & Laupland, 2008) . More attention needs to be paid to the global factors that contribute to the spread of these drug-resistance determinants that enter local health-care settings.
